Menu

Get in touch

Konradstrasse 12
8005 Zurich

Contact us

VC in Residence

Vi Partners

Age of VC

25 years old

Team size

12 team members

Locations

Altendorf

LinkedIn
Website
Portfolio

Fund volume

Asset under management of CHF 450M.

Focus stage / Vertical geographic 

60% Switzerland, and 40% rest of Europe.

Top investments 

amal logo

Lausanne-based immuno-oncology biotech developing next-generation therapeutic cancer vaccines. Acquired by Boehringer Ingelheim in 2019 to expand its cancer immunotherapy pipeline.

araris logo

Zurich-based biotech building a next-gen antibody-drug conjugate (ADC) platform using site-specific linker technology. Raised major Series A/B rounds to advance a pipeline of targeted cancer therapies.

nexthink logo

Lausanne-founded digital employee experience (DEX) platform using AI to monitor, analyze, and optimize IT environments in real time. Scaled to global enterprise adoption and acquired by Insight Partners–backed investors in a $1B+ transaction.

sumup logo

London- and Berlin-based fintech providing mobile point-of-sale and payment solutions for small businesses. Expanded into digital banking, invoicing, and financial services to build a full-stack SME platform.

Investment director

Olivier Laplace

Olivier Laplace Headshot

Software and financial engineer with 18 years of experience spanning software development, entrepreneurship, investment banking, and venture capital. Before joining Vi Partners, Olivier built and led Swiss Post’s corporate venture capital arm, spearheading 14 early-stage investments including Metaco (acquired by Ripple for $250M), TestingTime (acquired by Norstat), Bring! (acquired by Swiss Post), Beekeeper, and Hacknowledge.

Previously, he worked in corporate development at Kudelski, executing M&A transactions and founding the data analytics unit Nagra Insight, after earlier stints in investment banking at JPMorgan (London) and Citigroup (Paris). Olivier holds an MBA from IMD and began his career as a software developer.

Watchlist

Vi Partners focuses on enterprise AI, data infrastructure, and software that reshapes core business operations, with investments spanning agentic AI, unstructured-data intelligence, and AI-driven pricing and workflow automation. Portfolio companies include Unique, Kadoa, Buynomics, and Oplit across financial services and industrial use cases.

The firm applies the same computational lens to healthcare and life sciences, backing AI-enabled diagnostics (Altoida), data-driven drug discovery (Sibylla Biotech), and digital health platforms (Vara.ai, XO-life). Overall, Vi Partners targets technologies that move AI from experimentation to production across enterprise and medical workflows.